AIMS: To confirm and extend to primary care settings prior genome-wide association results that distinguish smokers who successfully quit from individuals who were not able to quit smoking in clinical trials. MATERIALS & METHODS: Affymetrix 6.0 Arrays were used to study DNA from successful quitters and matched individuals who did not quit from the Patch in Practice study of 925 smokers in 26 UK general practices who were provided with 15 mg/16 h nicotine-replacement therapy and varying degrees of behavioral support. RESULTS: Only a few SNPs provided results near 'genome-wide' levels of significance. Nominally significant (p < 0.01) SNP results identify the same chromosomal regions identified by prior genome-wide association studies to a much greater extent than expected by chance. CONCLUSION: Ability to change smoking behavior in a general practice setting appears to share substantial underlying genetics with the ability to change this behavior in clinical trials, though the modest sample sizes available for these studies provides some caution to these conclusions.
AIMS: To confirm and extend to primary care settings prior genome-wide association results that distinguish smokers who successfully quit from individuals who were not able to quit smoking in clinical trials. MATERIALS & METHODS: Affymetrix 6.0 Arrays were used to study DNA from successful quitters and matched individuals who did not quit from the Patch in Practice study of 925 smokers in 26 UK general practices who were provided with 15 mg/16 h nicotine-replacement therapy and varying degrees of behavioral support. RESULTS: Only a few SNPs provided results near 'genome-wide' levels of significance. Nominally significant (p < 0.01) SNP results identify the same chromosomal regions identified by prior genome-wide association studies to a much greater extent than expected by chance. CONCLUSION: Ability to change smoking behavior in a general practice setting appears to share substantial underlying genetics with the ability to change this behavior in clinical trials, though the modest sample sizes available for these studies provides some caution to these conclusions.
Authors: Qing-Rong Liu; Tomas Drgon; Donna Walther; Catherine Johnson; Oxanna Poleskaya; Judith Hess; George R Uhl Journal: Proc Natl Acad Sci U S A Date: 2005-08-09 Impact factor: 11.205
Authors: Tomas Drgon; Catherine Johnson; Donna Walther; Anthony P Albino; Jed E Rose; George R Uhl Journal: Mol Med Date: 2009-04-29 Impact factor: 6.354
Authors: Christina N Lessov; Nicholas G Martin; Dixie J Statham; Alexandre A Todorov; Wendy S Slutske; Kathleen K Bucholz; Andrew C Heath; Pamela A F Madden Journal: Psychol Med Date: 2004-07 Impact factor: 7.723
Authors: George R Uhl; Tomas Drgon; Catherine Johnson; Marco F Ramoni; Frederique M Behm; Jed E Rose Journal: Mol Med Date: 2010-08-24 Impact factor: 6.354
Authors: Marcus R Munafò; Elaine C Johnstone; Donna Walther; George R Uhl; Michael F G Murphy; Paul Aveyard Journal: Nicotine Tob Res Date: 2011-06-20 Impact factor: 4.244
Authors: Sean P David; Elaine C Johnstone; Michael Churchman; Paul Aveyard; Michael F G Murphy; Marcus R Munafò Journal: Nicotine Tob Res Date: 2011-01-25 Impact factor: 4.244
Authors: Jana Drgonova; Donna Walther; Katherine J Wang; G Luke Hartstein; Bryson Lochte; Juan Troncoso; Noriko Uetani; Yoichiro Iwakura; George R Uhl Journal: Mol Med Date: 2015-07-14 Impact factor: 6.354
Authors: Rashelle J Musci; Brian Fairman; Katherine E Masyn; George Uhl; Brion Maher; Danielle Y Sisto; Sheppard G Kellam; Nicholas S Ialongo Journal: Prev Sci Date: 2018-01
Authors: Jana Drgonova; Donna Walther; G Luke Hartstein; Mohammad O Bukhari; Michael H Baumann; Jonathan Katz; Frank Scott Hall; Elizabeth R Arnold; Shaun Flax; Anthony Riley; Olga Rivero-Martin; Klaus-Peter Lesch; Juan Troncoso; Barbara Ranscht; George R Uhl Journal: Mol Med Date: 2016-08-18 Impact factor: 6.354
Authors: K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur Journal: Clin Pharmacol Ther Date: 2013-03-18 Impact factor: 6.875